Author details

Full Name

Theodore S Johnson

Affiliation

ORCID

Career Start Year

2000

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
34614413	Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor TÂ cell immunity.	Immunity	2021
29693782	Access to hematopoietic stem cell transplant for patients with sickle cell anemia.	Pediatric Blood and Cancer	2018
30181177	Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy.	Cancer Research	2018
29343444	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6cCD103 Monocytic Antigen-Presenting Cells in Tumors.	Immunity	2018
27616578	Early career mentoring through the American Society of Pediatric Hematology/Oncology: Lessons learned from a pilot program.	Pediatric Blood and Cancer	2017
28488123	IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.	Cancer Immunology, Immunotherapy	2017
28322484	TFE3-positive renal cell carcinoma occurring in three children with dysfunctional kidneys on immunosuppression.	Pediatric Transplantation	2017
29275467	Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.	Advances in Experimental Medicine and Biology	2017
25054064	The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.	Journal for ImmunoTherapy of Cancer	2014
24259502	Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis.	Journal of Immunology	2014
24012416	Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes.	Immunity	2013
24038599	Complement protein C3 exacerbates prion disease in a mouse model of chronic wasting disease.	International Immunology	2013
22312408	Modulation of tumor tolerance in primary central nervous system malignancies.		2012
22679554	Incunabular immunological events in prion trafficking.	Scientific Reports	2012
23017145	Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.	Immunological Investigations	2012
23002439	Genetic depletion of complement receptors CD21/35 prevents terminal prion disease in a mouse model of chronic wasting disease.	Journal of Immunology	2012
21110979	Contemporary diagnostic methods for hemophagocytic lymphohistiocytic disorders.	Journal of Immunological Methods	2011
20559428	Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures.	PLoS ONE	2010
21113122	Monitoring immune cells trafficking fluorescent prion rods hours after intraperitoneal infection.	Journal of Visualized Experiments	2010
18952250	In vitro strain adaptation of CWD prions by serial protein misfolding cyclic amplification.	Virology	2008
15206713	Tryptophan catabolism and T cell responses.	Advances in Experimental Medicine and Biology	2003
11937528	Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses.	Journal of Immunology	2002
12228717	Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.	Science	2002
12385839	Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy.	Journal of Reproductive Immunology	2002
10720135	Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells.	Leukemia	2000